Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures/Disclaimer
- Objectives
- Cardio-Kidney-Metabolic (CKM) syndrome
- Cardiovascular outcomes – chronic kidney disease
- Cardiovascular outcomes – obesity
- Varieties of adiposity
- Background
- Definitions
- Stages of CKM
- Kidney Disease: Improving Global Outcomes (KDIGO) - CKD staging “heat map”
- Early stage and early life!
- Stage 2
- Stage 3 and 4
- Incorporation of social determinants of health
- Risk prediction
- Risk prediction: highlights of PREVENT
- Focus on therapeutics to minimize risk
- Non-steroidal mineralocorticoid receptor antagonists
- Glucagon-like peptide type 1 receptor agonists (GLP1RA)
- Sodium glucose cotransporter 2 inhibitor (SGLT2I)
- Challenges with CKMH care
- Summary
- Summary continued
- Thank you
Topics Covered
- Cardio-Kidney-Metabolic (CKM) syndrome
- Chronic Kidney Disease
- Obesity
- Varieties of adiposity
- Stages of CKM
- Risk prediction
- Non-steroidal mineralocorticoid receptor antagonists
- Glucagon-like peptide type 1 receptor agonists (GLP1RA)
- Sodium-glucose cotransporter 2 inhibitor (SGLT2I)
- Challenges with CKMH care
Links
Categories:
Therapeutic Areas:
External Links
Talk Citation
Mathew, R.O. (2024, July 31). Cardiovascular kidney metabolic syndrome [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/ZJWC8152.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mathew is an employee of the Veterans Health Administration but he is not currently speaking for the VHA. He serves on a Data Safety Monitoring Committee through Advarra central IRB.
A selection of talks on Metabolism & Nutrition
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, My name is Roy Mathew.
I'm an associate
professor of medicine at
the Loma Linda University
School of Medicine.
As well I am a nephrologist at
the Loma Linda VA
Healthcare System.
I'll be talking to
you today about
cardiovascular kidney
metabolic syndrome.
0:15
My disclosures and
disclaimers include:
I'm currently an employee of
the Veterans Health
Administration of
the United States
federal government
but I am not currently speaking
for the Veterans
Health Administration
or the federal government.
I do serve on a Data Safety
Monitoring Committee
through a central IRB
called Advarra central IRB.
0:35
The objectives for this talk
will include an overview of
the pathophysiologic connections
between cardiovascular,
kidney and metabolic
diseases, discuss the novel
cardiovascular-kidney-metabolic
syndrome and its staging,
discuss novel therapeutics
and risk prediction
for CKMH the abbreviation for
cardiovascular-kidney-metabolic
health and then suggest
future challenges for the
implementation of care around CKMH.
1:05
So why cardio-kidney-metabolic
syndrome or CKM.
We're familiar with the
separate components
of this new syndrome.
So first we'll start with
cardiorenal syndrome.
The interrelationship
between heart disease and
kidney disease has been well
described for several decades
now that dysfunction in
one organ leads to or
worsens dysfunction
in the other organ
either heart disease
or kidney disease.
But we're also aware that
metabolic syndrome can
tighten this relationship.
In addition, the term
cardiometabolic syndrome
has been around for
similar periods of time
and that has recognized
that on top of the
metabolic syndrome which includes
blood pressure elevation,
impaired fasting
glucose and obesity
adversely affects
the heart and then
heart disease is
worsening this scenario.
In this situation,
we frequently encounter
kidney disease as well.
The logical conclusion
would be that we
need to consider
all of these when
we're dealing with patients
with these syndromes
because the interaction will
affect all three systems.
So the relationship between
heart disease, kidney disease,
and metabolic syndrome is always
going to be present
and it's important as
clinicians who care
for these patients
to be able to see the
relationship of all of
these and to come up with
treatments and treatment
plans that will help
manage all of these
conditions because of
the relationship and
worsening outcomes.